191 related articles for article (PubMed ID: 21656049)
1. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
2. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
3. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
[TBL] [Abstract][Full Text] [Related]
5. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Yamane T; Takaoka A; Kita M; Imai Y; Senda M
Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI.
Kusunoki S; Terao Y; Ujihira T; Fujino K; Kaneda H; Kimura M; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2017 Aug; 56(4):508-513. PubMed ID: 28805609
[TBL] [Abstract][Full Text] [Related]
7. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
8. Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an
Tsujikawa T; Yamamoto M; Shono K; Yamada S; Tsuyoshi H; Kiyono Y; Kimura H; Okazawa H; Yoshida Y
Ann Nucl Med; 2017 Dec; 31(10):752-757. PubMed ID: 28905201
[TBL] [Abstract][Full Text] [Related]
9. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
11. A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with
Nakagawa M; Nakaura T; Namimoto T; Iyama Y; Kidoh M; Hirata K; Nagayama Y; Oda S; Sakamoto F; Shiraishi S; Yamashita Y
Clin Radiol; 2019 Feb; 74(2):167.e1-167.e7. PubMed ID: 30471748
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose uptake in uterine leiomyomas in healthy women.
Tsukada H; Murakami M; Shida M; Kikuchi K; Watanabe M; Yasuda S; Suzuki Y
Clin Imaging; 2009; 33(6):462-7. PubMed ID: 19857807
[TBL] [Abstract][Full Text] [Related]
13. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
[TBL] [Abstract][Full Text] [Related]
14. Uptake of 2-[18F]fluoro-2-deoxy-D-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography.
Ak I; Ozalp S; Yalçin OT; Zor E; Vardareli E
Nucl Med Commun; 2004 Sep; 25(9):941-5. PubMed ID: 15319600
[TBL] [Abstract][Full Text] [Related]
15. High metabolic characteristics of uterine fibroids in 18F-FDG PET/CT imaging and the underlying mechanisms.
Ma Y; Shao X; Shao X; Wang X; Wang Y
Nucl Med Commun; 2016 Nov; 37(11):1206-11. PubMed ID: 27281358
[TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET in detecting uterine leiomyoma.
Lin CY; Ding HJ; Chen YK; Liu CS; Lin CC; Kao CH
Clin Imaging; 2008; 32(1):38-41. PubMed ID: 18164393
[TBL] [Abstract][Full Text] [Related]
17. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas.
Nagamatsu A; Umesaki N; Li L; Tanaka T
Oncol Rep; 2010 Apr; 23(4):1069-76. PubMed ID: 20204293
[TBL] [Abstract][Full Text] [Related]
18.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of FDG PET/CT findings of uterine tumors.
Kitajima K; Murakami K; Kaji Y; Sugimura K
AJR Am J Roentgenol; 2010 Sep; 195(3):737-43. PubMed ID: 20729454
[TBL] [Abstract][Full Text] [Related]
20. F-18 fluorodeoxyglucose uptake in leiomyomatous uterus.
Shida M; Murakami M; Tsukada H; Ishiguro Y; Kikuchi K; Yamashita E; Kajiwara H; Yasuda M; Ide M
Int J Gynecol Cancer; 2007; 17(1):285-90. PubMed ID: 17291269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
